Evidence map›Paper›PMID 35958274›Full record

ArticleDose-response : a publication of International Hormesis Society

Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung Adenocarcinoma.

Vera Jokic, Katarina Savic-Vujovic, Jelena Spasic, Zoran Bukumiric, Mladen Marinkovic, Davorin Radosavljevic, Milena Cavic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vera JokicClinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Katarina Savic-VujovicDepartment of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.ORCID https://orcid.org/0000-0002-4701-6291
Jelena SpasicClinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.ORCID https://orcid.org/0000-0002-1386-9114
Zoran BukumiricDepartment of Statistics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Mladen MarinkovicClinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Davorin RadosavljevicClinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Milena CavicDepartment of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.ORCID https://orcid.org/0000-0002-7604-9295
Oncology Institute of Vojvodina · RSUniversity of Belgrade · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The aim of this research was to evaluate clinical and low-cost genetic determinants of treatment outcome in Material and Methods: Results: Patients were treated with EGFR-TKIs for a period of 1-39months (median 9), with a median PFS of 12.0 months (10.4-13.6, CI 95%), and a median OS of 19.0 months (15.1-22.7, CI 95%). The presence of pain was significantly correlated with the existence of bone ( Conclusions:

Indexed as

EGFRlung cancerpaintyrosine kinase inhibitors

Identifiers

PMID35958274
PMCPMC9358214
OpenAlexW4289755923

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.